Skip to content

Study Details

A First-In-Human (FIH) Study of Inhibitory Interneurons (NRTX-1001) in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (MTLE)

(IRB#: IRB_00157503)

NRTX-1001 is a study drug to help people with drug-resistant mesial temporal lobe epilepsy MTLE. We need to learn the safety and effectiveness of NRTX-1001 for it to be approved by the Federal Drug Administration (FDA) and used to help people with MTLE. The information we gain may aid future patients.


  • All genders
  • Over 18 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 18 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 18 to 65 years old
  • Cannot control seizures despite using other study drugs
  • Females who may become pregnant must use birth control
  • Have at least a 10th-grade education
  • Able to read and speak English or Spanish

Exclusion Criteria

  • Epilepsy from another progressive disease
  • Another severe medical issue that prevents participation
  • Suicide attempt in the past year of participation
  • Severe mental health issue(s)
  • Pregnant or breast feeding

Will I be paid for my time?


For more information contact:

Laura Beeler


IRB#: IRB_00157503

PI: Amir Arain

Department: NEUROLOGY

Approval Date: 2022-11-17 07:00:00

Study Categories: Brain Health Studies

Specialties: Neurology, Neurosurgery

Last Updated: 6/8/23